Recent Updates
Recently added Catalysts
EQ Positive Sentiment

Equillium to Participate in Oppenheimer’s 2026 Innovation on the Island Event

Monday, April 20, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Equillium, Inc. will present at Oppenheimer's 2026 Innovation on the Island Event on April 28, 2026. The management team will also be available for investor meetings. The company focuses on developing novel therapies for severe autoimmune and inflammatory disorders, with its lead candidate EQ504 showing promise in treating conditions like ulcerative colitis.
Price reaction · baseline $2.05 (2026-04-17 close) · 1 other EQ headline(s) in the window, move may be shared
day 0 close · peak
-2%

Market Sentiment Analysis

POSITIVE FACTORS

  • Equillium is presenting at a notable investor event.
  • The company is developing innovative therapies for severe disorders.
  • Management will engage with investors, indicating growth potential.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+58%
120-day peak, hindsight
Typical move
2.1%
average across 2 past catalysts
Cash runway
~42 mo
Minimal dilution risk
Lead asset
BNZ132-1-40
Phase 1 · Safety and Tolerability in Healthy Subjects

Full Press Release Details

LA JOLLA, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Equillium, Inc. (Nasdaq: EQ), a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders, today announced that management will be presenting at Oppenheimer’s 2026 Innovation on the Island Event on Tuesday April 28, 2026 at 7:50am AST.
Members of the Equillium management team will be available to meet with investors who are registered to attend the conference.
About EquilliumEquillium is a biotechnology innovator developing novel therapies to treat severe autoimmune and inflammatory disorders. The company’s lead therapeutic candidate is EQ504, a potent and selective aryl hydrocarbon receptor (AhR) modulator designed with a multi-modal, non-immunosuppressive mechanism of action to be complementary to other inflammation and immunology agents. EQ504 is an investigational therapeutic program with potential for targeted, local delivery via enteric coating for the treatment of ulcerative colitis and other gastrointestinal diseases or inhaled formulations for the treatment of inflammatory lung diseases.
For more information, visitwww.equilliumbio.com.

Investor ContactPJ KelleherLifeSci Advisors, LLC+1-617-430-7579pkelleher@lifesciadvisors.com

Frequently Asked Questions

When is Equillium presenting at the event?

Equillium will present on April 28, 2026, at 7:50am AST.

What is the focus of Equillium's therapies?

Equillium develops therapies for severe autoimmune and inflammatory disorders.

What is EQ504?

EQ504 is an investigational therapy designed to treat ulcerative colitis and lung diseases.

Who can meet with Equillium's management?

Registered investors at the conference can meet with Equillium's management team.

ShareAdd on Google
Tags: EQ Viatris Investor Conferences Healthcare Equillium Oppenheimer 2026 EQ504 biotechnology autoimmune disorders
Last updated: Apr 20, 2026

Biotech snapshot

Cash runway
$57M liquidity · $1M/mo burn
~42 mo
Minimal dilution risk
Lead asset
BNZ132-1-40Phase 1
Safety and Tolerability in Healthy Subjects →

Catalyst track record

+58%
best trade around EQ's most recent catalyst

Peak hindsight return over a 120-day window, across 2 tracked FDA/PDUFA catalysts for EQ.

See every catalyst's timing & PoA →